CVE-2024-47530 json
Scout contains an Open Redirect on Login via `next`
published 2024-09-30 2 y ago modified 2026-06-17 4 mo ago also EUVD-2024-42515
- cvss
- 5.4
- version 3.1, CNA
- cisa kev
- Not listed
- not in CISA's catalog
- epss
- 0.4%
- EPSS 0.4% chance of exploitation in 30 days, percentile 33%
- public exploits
- 0
- none known
Summary
Scout is a web-based visualizer for VCF-files. Open redirect vulnerability allows performing phishing attacks on users by redirecting them to malicious page. /login API endpoint is vulnerable to open redirect attack via next parameter due to absence of sanitization logic. Additionally, due to lack of scheme validation, HTTPS Downgrade Attack can be performed on the users. This vulnerability is fixed in 4.89.
Patch / fix
- Clinical-Genomics scout 4.89
- gstreamer-plugins-good openSUSE Tumbleweed 1.24.10-2.1
opensuse advisories openSUSE-SU-2024:14578-1
CISA SSVC
- Exploitation
- Proof of concept is public
- Automatable
- no
- Technical impact
- partial
- Assessed
- 2 y ago
Exploit prediction
0.39% chance of exploitation in the next 30 days, higher than 33% of all scored CVEs (FIRST EPSS, 2026-11-08).
Exploits and checks
- github.com https://github.com/Clinical-Genomics/scout/security/advisories/GHSA-3x45-2m34-x95v referenced PoC, tagged "exploit" by a source, unverified
CVSS scores
| assigned by | version | score | vector |
|---|---|---|---|
| CNA | 3.1 | 5.4 | CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N |
| NVD | 3.1 | 6.1 | CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N |
Affected products
- Clinical-Genomics scout
Classification
- Weakness
-
- CWE-601 URL Redirection to Untrusted Site
References
Sources
- CVE List CVE-2024-47530
- NVD CVE-2024-47530
Fencer Vulns keeps one entry per vulnerability: the CVE id wins, then GHSA, and records that alias each other are merged, except that two CVEs always keep separate entries. The same data is available as JSON.
CPEs and fixed versions use Anchore's correction of NVD's data: Added CPE configurations because not yet analyzed by NVD.